Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 8
Submit an article Journal homepage
39
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide

Clara Montagut Department of Hematology, Institute of Hematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, SpainCorrespondence[email protected]
,
Francesc Bosch Department of Hematology, Institute of Hematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
,
Luís Villela Department of Hematology, Institute of Hematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
,
Laura Rosiñol Department of Hematology, Institute of Hematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
&
Joan Bladé Department of Hematology, Institute of Hematology and Oncology (ICMHO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain
Pages 1711-1712 | Received 03 Oct 2003, Published online: 26 Aug 2009

References

  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1993) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine, 341, 1606— 1609.
  • Blade, J., Esteve, J., Rosifiol, L., Perales, M., Montoto, S., Tuset, M., et al. (2001) "Thalidomide in refractory and relapsing multiple myeloma", Seminars in Oncology, 28, 588 — 592.
  • Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identi-fication of prognostic factors in a phase 2 study of 169 patients", Blood, 98, 492–494.
  • Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F., Ballerini, F., et al. (2002) "Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma", Haematologica, 87, 408–414.
  • Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Maim, C. (2000) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", British Journal of Haematology, 109, 89 — 96.
  • Kneller, A., Raanani, P., Hardan, I., Avigdor, A., Levi, I., Berkowicz, M., et al. (2000) "Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug", British Journal of Haematology, 108, 391 — 393.
  • Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., et al. (2001) "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and che-motherapy", Blood, 98, 1614 — 1615.
  • Osman, K., Comenzo, R. and Rajkumar, S.V. (2001) "Deep venous thrombosis and thalidomide therapy for multiple myeloma", New England Journal of Medicine, 344, 1951— 1952.
  • Solomon, A., Weiss, D.T. and Kattine, A.A. (1991) "Nephrotoxic potential of Bence Jones proteins", New England Journal of Medicine, 324, 1845— 1851.
  • Blade, J., Fernandez-Llama, P., Bosch, F., Montoliu, J., Lens, X.M., Montoto, S., et al. (1998) "Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution", Archives of Internal Medicine, 158, 1889— 1893.
  • Clark, A.D., Shetty, A. and Soutar, R. (1999) "Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma", Blood Reviews, 13, 79 — 90.
  • Coca, A., Blade, J., Martinez, A., Segura, F., Soriano, E. and Ribas-Mundo, M. (1979) "Tobramycin nephrotoxicity. A prospective clinical study", Postgraduate Medical Journal, 55, 791— 796.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.